Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
about
Treatment of systemic sclerosis: is there any hope for the future?Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.The therapeutic landscape of non-alcoholic steatohepatitis.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.Distinct but complementary contributions of PPAR isotypes to energy homeostasis.Novel Anti-fibrotic Therapies.Current and future pharmacological therapies for NAFLD/NASH.Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.Use of biologics and other novel therapies for the treatment of systemic sclerosis.Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression.The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis.
P2860
Q38834999-FB68A30D-0F34-4233-8AC9-A9FE45729966Q38956376-BF63F9F9-C6E2-4A47-B763-066E62EC3A52Q38978011-E40FDFBC-7421-42B2-B6D5-2744EF3CC9CFQ39090639-19C4C476-4FBB-4A7B-A790-19C239C6B410Q39214885-52B4E8C7-C11F-4DE7-935B-38EE4EE9F48BQ39377055-E4FC4B95-EE5B-4C82-8599-062FC69A63F8Q47778507-FBE46531-5C4F-4C65-A032-7F4DB84743EEQ50230077-99AB4095-A2BD-4ED0-8DFE-2E6A26CB889AQ51297193-A6D29612-D030-40A3-B34A-9A4802369B55Q52605977-EAADFAFF-6CA3-4F99-BA4A-22F942E97D50Q52699074-139105B7-ABC8-4091-9ABC-4977A296B446Q52726337-E722A00B-2413-4D04-B9F9-0641D5FFE79F
P2860
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@en
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@nl
type
label
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@en
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@nl
prefLabel
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@en
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@nl
P2093
P2860
P1476
Pan PPAR agonist IVA337 is eff ...... of experimental skin fibrosis.
@en
P2093
Camelia Frantz
Jean-Louis Junien
Jean-Michel Luccarini
Matthieu Ponsoye
Nadira Ruzehaji
Pierre Broqua
Sonia Pezet
Thomas Guilbert
Yannick Allanore
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-208029
P407
P577
2016-03-09T00:00:00Z